The CPGR is a nonprofit organization funded by the Technology Innovation
Agency (TIA), which is based on an initiative by the Department of
Science and Technology (DST) whose goal is to develop the bio-economy in
South Africa. According to Dr Reinhard Hiller, Managing Director of the
CPGR, “The high throughput capability of GeneTitan® MC
Instrument combined with customizable
Axiom® Genotyping Arrays is ideal for meeting the needs
of scientists in Africa whose research projects range from small pilot
to large-scale discovery to focused validation studies. GeneTitan®
MC Instrument expands our genomics service capabilities and will further
enable CPGR to support cutting-edge translational research in Africa.
Further, it allows discovery and validation of disease-related
biomarkers economically – even when searching for very rare genetic
variants. We expect to progress personalized medicine studies that aim
to discover genetic markers specific in the African population for
better diagnosis and drug treatment.”

It is a well-known fact that genetic variability of African populations
is far greater than in other regions in the world. This is particularly
important when considering that African populations are underrepresented
in most studies on hereditary diseases and pharmacogenomics. Applying
these types of genomic discoveries to clinical practices has the
potential to change health and wellness of African populations.

“We are excited to partner with CPGR and see this as a significant
opportunity to ensure that African populations are represented in
genomics research studies leading to personalized therapies. Affymetrix
is leading the way in population optimized genotyping analysis and was
the first to create a genotyping array with content derived specifically
from African populations,” said Chris Barbazette, VP of Commercial
Operations, International Markets at Affymetrix.

Products mentioned in this release are for research use only. Not for
diagnostic procedures.

PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®,
GeneChip®, GeneTitan®, QuantiGene®,
SensationPlusTM, and all other trademarks are the property of
Affymetrix, Inc. All other trademarks are the property of their
respective owners.

About the CPGR

The CPGR
is a specialist not-for-profit contract research organization
established in South Africa through funding by the Technology Innovation
Agency (TIA) to provide support and services to the life science and
biotech community. It is based on an initiative by the Department
of Science and Technology (DST) to boost the development of a
bio-economy in South Africa. The CPGR combines state-of-the-art
information rich genomic and proteomic ('omics') technologies with
bio-computational pipelines, and biological models, to create unique
solutions in the human health and the agri-biotech sectors. Please visit www.cpgr.org.za
for more information or contact Dr Reinhard Hiller at reinhard.hiller@cpgr.org.za.

About Affymetrix

Affymetrix technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and nonprofit research institutes. More than 26,000
peer-reviewed papers have been published citing the technologies.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Santa Clara, San Diego, Cleveland, Ohio,
Singapore, and Austria. The company has about 1,180 employees worldwide
and maintains sales and distribution operations across Europe, Asia, and
Latin America. For more information about Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies" or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31, 2011,
and other SEC reports for subsequent quarterly periods.